Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University Health Science Center, No. 38 Xueyuan Road, Beijing, 100191, China.
Medical Intensive Care Unit, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, 100730, China.
Sci Rep. 2024 May 28;14(1):12206. doi: 10.1038/s41598-024-62630-x.
Atrial fibrillation (AF) is the most common arrhythmia and its incidence increases with sepsis. However, data on new-onset AF during sepsis hospitalization remain limited in China. We aimed to evaluate the incidence, risk factors, and associated mortality of new-onset AF in sepsis patients in China. We conducted a retrospective study using the National Data Center for Medical Service system, from 1923 tertiary and 2363 secondary hospitals from 31 provinces in China from 2017 to 2019.In total we included 1,425,055 sepsis patients ≥ 18 years without prior AF. The incidence of new-onset AF was 1.49%. Older age, male sex, hypertension, heart failure, coronary disease, valvular disease, and mechanical ventilation were independent risk factor. New-onset AF was associated with a slight increased risk of mortality (adjusted RR 1.03, 95% CI 1.01-1.06). Population attributable fraction suggested AF accounted for 0.2% of sepsis deaths. In this large nationwide cohort, new-onset AF occurred in 1.49% of sepsis admissions and was associated with a small mortality increase. Further research should examine whether optimized AF management can improve sepsis outcomes in China.
心房颤动（AF）是最常见的心律失常，其发病率随着脓毒症的发生而增加。然而，中国关于脓毒症住院期间新发 AF 的数据仍然有限。我们旨在评估中国脓毒症患者新发 AF 的发生率、危险因素和相关死亡率。我们使用国家医疗服务系统数据中心，对来自中国 31 个省的 1923 家三级医院和 2363 家二级医院，对 2017 年至 2019 年期间≥18 岁且无先存 AF 的 1425055 例脓毒症患者进行了回顾性研究。新发 AF 的发生率为 1.49%。年龄较大、男性、高血压、心力衰竭、冠心病、瓣膜病和机械通气是独立的危险因素。新发 AF 与死亡率略有增加相关（调整 RR 1.03，95%CI 1.01-1.06）。人群归因分数表明 AF 占脓毒症死亡的 0.2%。在这项大规模的全国性队列研究中，新发 AF 发生在 1.49%的脓毒症入院患者中，与死亡率略有增加相关。进一步的研究应探讨优化 AF 管理是否可以改善中国脓毒症患者的结局。
